AVASARALA, J. Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill. Drug Target Insights, [S. l.], v. 11, n. 1, 2017. DOI: 10.33393/dti.2017.1367. Disponível em: https://journals.aboutscience.eu/index.php/dti/article/view/1367. Acesso em: 3 jul. 2024.